ProtoKinetix’ AAGP™ Protects Cells While Preserving Normal Cell Function

PROTOKINETIX INC. (PKTX: OTCBB)
Vancouver, British Columbia, July 19, 2006

As previously reported, ProtoKinetix has completed extensive testing of the effects of AAGP™ on a variety of cell lines using a wide range of concentrations. These results have culminated in the recent announcements that reported the powerful protective effect of the family of AAGP™ molecules against even the most harsh stresses. It is critical that preservative molecules can achieve these extremely high levels of protection without interfering with the normal cell function.

PKTX is pleased to report that the results of experiments done by ProteoCell Laboratories have demonstrated that the presence of AAGP™ maintains normal cell function. ProteoCell has observed that, even over an extended period of time, the cellular function and growth rate of cells treated with AAGP™ is identical to cells not treated with ProtoKinetix’ anti-aging molecules. This family of molecules prolongs the lifespan and health of cells without having any adverse or negative effects on cell characteristics.

About ProtoKinetix:

ProtoKinetix Inc. is a Biotechnical Company dedicated to the development of a family of synthetic antifreeze glycoproteins (AAGP™) for human and veterinary medicine, the biotechnology and cosmetic industries, and as a food additive. Using previously published research on native antifreeze proteins and antifreeze glycoproteins as a guide, and coordinating a vast pool of world recognized intellectual talent in a networked environment, PKTX is conducting rapid and meaningful research with a view to developing markets for this very useful family of molecules. Sign up for free automatic email news alerts at our new website at: www.protokinetix.com

The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for forward-looking statements.  Some information included in this press release contains statements that are forward-looking.  Such forward-looking information involves significant risks and uncertainties that could affect anticipated results in the future and, accordingly, these results may differ materially from those expressed in any forward-looking statements made by or on behalf of the Company.  For a description of additional risks and uncertainties, please refer to the Company’s filings with the Securities and Exchange Commission.

On behalf of the Board of Directors,

Dr. John Todd - President

Company Office:                       
Suite # 1500           
885 West Georgia Street           
Vancouver, BC  V6C 3E8           

Investor Contact:
BCGU, Business Consulting Group Unlimited
In the U.S.:  (888) 772-1288
Outside the U.S.: (760) 230.2300 ext 206